Cargando…
Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700499/ https://www.ncbi.nlm.nih.gov/pubmed/23826449 http://dx.doi.org/10.12659/AJCR.889109 |
_version_ | 1782275518866915328 |
---|---|
author | Nakashima, Hiroshi Umeyama, Yasuhiro Minami, Kazutoshi |
author_facet | Nakashima, Hiroshi Umeyama, Yasuhiro Minami, Kazutoshi |
author_sort | Nakashima, Hiroshi |
collection | PubMed |
description | BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditions are resistant to aggressive management. CASE REPORT: We present a case of fulminant myocarditis that rapidly progressed to cardiogenic shock and in-hospital cardiac arrest in a 46-year-old male. The patient promptly received inotropic agents, intra-aortic balloon pump therapy, and extracorporeal membrane oxygenation. However, creatinine kinase (CK), C-reactive protein (CRP), and QRS width increased significantly between days 1 and 3 of treatment; the patient’s hemodynamic profile deteriorated despite this treatment regimen. Intravenous methylprednisolone was initiated on day 3 at a dose of 1,000 mg/day and maintained for an additional three days. Less than 24 h after methylprednisolone administration, the QRS width decreased significantly from 0.44 s to 0.18 s. In addition, CK and CRP levels declined sharply, which is associated with hemodynamic improvement. CONCLUSIONS: High doses of intravenous methylprednisolone may be considered a therapeutic option for patients with fulminant myocarditis that is refractory to usual management practices. |
format | Online Article Text |
id | pubmed-3700499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-37004992013-07-03 Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support Nakashima, Hiroshi Umeyama, Yasuhiro Minami, Kazutoshi Am J Case Rep Case Report BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditions are resistant to aggressive management. CASE REPORT: We present a case of fulminant myocarditis that rapidly progressed to cardiogenic shock and in-hospital cardiac arrest in a 46-year-old male. The patient promptly received inotropic agents, intra-aortic balloon pump therapy, and extracorporeal membrane oxygenation. However, creatinine kinase (CK), C-reactive protein (CRP), and QRS width increased significantly between days 1 and 3 of treatment; the patient’s hemodynamic profile deteriorated despite this treatment regimen. Intravenous methylprednisolone was initiated on day 3 at a dose of 1,000 mg/day and maintained for an additional three days. Less than 24 h after methylprednisolone administration, the QRS width decreased significantly from 0.44 s to 0.18 s. In addition, CK and CRP levels declined sharply, which is associated with hemodynamic improvement. CONCLUSIONS: High doses of intravenous methylprednisolone may be considered a therapeutic option for patients with fulminant myocarditis that is refractory to usual management practices. International Scientific Literature, Inc. 2013-04-23 /pmc/articles/PMC3700499/ /pubmed/23826449 http://dx.doi.org/10.12659/AJCR.889109 Text en © Am J Case Rep, 2013 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Case Report Nakashima, Hiroshi Umeyama, Yasuhiro Minami, Kazutoshi Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title | Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title_full | Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title_fullStr | Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title_full_unstemmed | Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title_short | Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
title_sort | successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700499/ https://www.ncbi.nlm.nih.gov/pubmed/23826449 http://dx.doi.org/10.12659/AJCR.889109 |
work_keys_str_mv | AT nakashimahiroshi successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport AT umeyamayasuhiro successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport AT minamikazutoshi successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport |